ETFs with exposure to EXACT Sciences Corp. : November 17, 2017 Fri, 17 Nov 2017 16:50:48 +0000 Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to EXACT Sciences Corp. Here are 5 ETFs with the largest exposure to EXAS-US. Comparing the performance and risk of EXACT Sciences Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more
(Read more...)
Exact Sciences breaks ground on lab, office expansions in Madison Wed, 15 Nov 2017 22:48:44 +0000 Exact Sciences Corp. broke ground last week on construction of new laboratory facilities on the Madison campus of the former Spectrum Brands Holdings as part of an expansion effort that would allow for the addition of 1,000 employees. The Madison-based biotechnology firm, which produces and markets the Cologuard noninvasive stool DNA-based colon cancer screening test, is also planning a renovation of an office building in that campus where it now houses 350 employees in its customer care, IT and administrative teams.
Even Exact Sciences Bulls Wonder If Expectations Are Lofty Mon, 13 Nov 2017 18:07:10 +0000 EXACT Sciences Corporation (NASDAQ: EXAS ) shares have been on a heady run this year. Despite the sell side's optimism on the company's fundamentals, analysts have become wary of Exact's astronomical ...
Exact Sciences to Expand Laboratory and Corporate Facilities in Madison Wed, 08 Nov 2017 19:00:00 +0000 Combined lab operations will provide Exact Sciences the capacity to deliver more than 4.5 million Cologuard results per year. Alongside team members, community partners and city officials, Exact Sciences chairman and CEO Kevin Conroy announced the company will build additional laboratory facilities at 650 Forward Drive on the City of Madison's near west side.
Halozyme is a biopharmaceutical company developing and commercializing products based on the extracellular matrix for the drug delivery, oncology, and dermatology markets.
Halozyme Therapeutics To Participate In Upcoming Healthcare Conferences Wed, 15 Nov 2017 13:00:00 +0000 SAN DIEGO , Nov. 15, 2017 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies will participate in two upcoming investor ...
Merrimack (MACK) Q3 Loss Narrower than Expected, Stock Up Thu, 09 Nov 2017 14:45:02 +0000 Merrimack (MACK) reported narrower-than-expected loss in the third quarter. With no marketed product after Onivyde sale, the company is now focused on developing its pipeline candidates.
Adaptimmune Therapeutics Plc :ADAP-US: Earnings Analysis: Q3, 2017 By the Numbers : November 8, 2017 Wed, 08 Nov 2017 19:40:11 +0000 Categories: Yahoo FinanceGet free summary analysis Adaptimmune Therapeutics Plc reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Adaptimmune Therapeutics Plc – Affimed N.V. and Axovant Sciences Ltd (AFMD-US and AXON-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD 28.23 million, ... Read more
(Read more...)
Adaptimmune marks Official Opening of U.K. Headquarters Mon, 06 Nov 2017 13:09:21 +0000 PHILADELPHIA and OXFORD, U.K., Nov. 06, 2017-- Adaptimmune Therapeutics plc, a leader in T-cell therapy to treat cancer, today announced that it will host an official opening ceremony at its new U.K. headquarters ...
Roche Reports Positive Data From Tecentriq Combination Study Mon, 20 Nov 2017 15:02:03 +0000 Roche (RHHBY) announced encouraging results from IMpower150 study evaluating the efficacy and safety of Tecentriq in combination with chemotherapy (carboplatin and paclitaxel), with or without Avastin.
Corcept Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : CORT-US : November 20, 2017 Mon, 20 Nov 2017 12:57:52 +0000 Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Corcept Therapeutics, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bullish ... Read more
(Read more...)
Incyte (INCY) Initiates Essential Thrombocythemia Trial Thu, 16 Nov 2017 12:55:12 +0000 Incyte (INCY) announced that the first patient has been treated in the essential thrombocythemia trial on ruxolitinib. A potential label expansion of the drug will boost sales.
Mirati Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares Mon, 20 Nov 2017 21:15:00 +0000 SAN DIEGO, Nov. 20, 2017 /PRNewswire/ -- Mirati Therapeutics, Inc. (MRTX) today announced the closing of its previously announced underwritten public offering of 2,938,986 shares of its common stock at a public offering price of $13.00 per share. This includes the exercise in full by the underwriters of their option to purchase up to 923,085 additional shares of common stock. In addition, and in lieu of common stock, Mirati sold to certain investors pre-funded warrants to purchase up to an aggregate of 4,137,999 shares of common stock at a purchase price of $12.999 per warrant, which represents the per share public offering price for the common stock less the $0.001 per share exercise price for each such pre-funded warrant. The aggregate gross proceeds to Mirati from this offering were approximately $92.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Mirati.
Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock Thu, 16 Nov 2017 13:45:00 +0000 SAN DIEGO, Nov. 16, 2017 /PRNewswire/ -- Mirati Therapeutics, Inc. (MRTX) today announced the pricing of an underwritten public offering of 2,015,901 shares of its common stock at a price to the public of $13.00 per share. In addition, and in lieu of common stock, Mirati is offering to certain investors pre-funded warrants to purchase up to an aggregate of 4,137,999 shares of common stock at a purchase price of $12.999 per warrant, which represents the per share public offering price for the common stock less the $0.001 per share exercise price for each such pre-funded warrant. The gross proceeds from this offering are expected to be approximately $80.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Mirati. Mirati has granted the underwriters a 30-day option to purchase up to an additional 923,085 shares of common stock in connection with the public offering.
Mirati Therapeutics Announces Proposed Public Offering Of Common Stock Wed, 15 Nov 2017 21:01:00 +0000 SAN DIEGO, Nov. 15, 2017 /PRNewswire/ -- Mirati Therapeutics, Inc. (MRTX) today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock. Mirati expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. All of the shares are being offered by Mirati.
Mirati Therapeutics Announces Advancement Of First-In-Class Opportunities With Sitravatinib And KRAS Inhibitor Programs Mon, 13 Nov 2017 21:15:00 +0000 SAN DIEGO, Nov. 13, 2017 /PRNewswire/ -- Mirati Therapeutics, Inc. (MRTX) (the Company or Mirati), a clinical-stage targeted oncology company, today announced that it is reprioritizing its development programs to capitalize on encouraging data and development opportunities in its sitravatinib and KRAS programs. In addition, the Company announced that it has selected a clinical lead and backup compounds in its KRAS program that potently target KRAS G12C mutations.
Mirati reports 3Q loss Thu, 02 Nov 2017 09:49:49 +0000 The San Diego-based company said it had a loss of 65 cents per share. The results surpassed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for ...
Mirati Therapeutics Reports Third Quarter 2017 Financial Results Wed, 01 Nov 2017 20:30:00 +0000 SAN DIEGO , Nov. 1, 2017 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage oncology biotechnology company, reported financial results for the third quarter 2017. "We are excited ...
ANI Pharmaceuticals develops, manufactures and markets top quality prescription and over-the-counter pharmaceuticals, made in the U.S.A.
ETFs with exposure to ANI Pharmaceuticals, Inc. : November 16, 2017 Thu, 16 Nov 2017 16:09:47 +0000 Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to ANI Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to ANIP-US. Comparing the performance and risk of ANI Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more
(Read more...)
ANI Pharmaceuticals, Inc. :ANIP-US: Earnings Analysis: Q3, 2017 By the Numbers : November 3, 2017 Fri, 03 Nov 2017 14:01:58 +0000 Categories: Yahoo FinanceGet free summary analysis ANI Pharmaceuticals, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of ANI Pharmaceuticals, Inc. – Pfizer Inc. and Novartis AG Sponsored ADR (PFE-US and NVS-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD 48.16 ... Read more
(Read more...)
ANI posts 3Q profit Thu, 02 Nov 2017 13:11:17 +0000 On a per-share basis, the Baudette, Minnesota-based company said it had net income of 40 cents. Earnings, adjusted for one-time gains and costs, were $1.11 per share. The drugmaker posted revenue of $48.2 ...
ETFs with exposure to ANI Pharmaceuticals, Inc. : October 16, 2017 Mon, 16 Oct 2017 13:48:04 +0000 Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to ANI Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to ANIP-US. Comparing the performance and risk of ANI Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more
(Read more...)
ANI Pharmaceuticals Inc (ANIP): Can It Deliver A Superior ROE To The Industry? Mon, 02 Oct 2017 17:22:12 +0000 ANI Pharmaceuticals Inc’s (NASDAQ:ANIP) most recent return on equity was a substandard 3.11% relative to its industry performance of 18.27% over the past year. An investor may attribute an inferiorRead More...
ETFs with exposure to ANI Pharmaceuticals, Inc. : September 19, 2017 Tue, 19 Sep 2017 20:58:09 +0000 Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to ANI Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to ANIP-US. Comparing the performance and risk of ANI Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more
(Read more...)
ANI Pharmaceuticals, Inc. :ANIP-US: Earnings Analysis: Q2, 2017 By the Numbers : September 5, 2017 Tue, 05 Sep 2017 16:41:15 +0000 Categories: Yahoo FinanceGet free summary analysis ANI Pharmaceuticals, Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of ANI Pharmaceuticals, Inc. – VIVUS, Inc., Jazz Pharmaceuticals Plc, Pfizer Inc., Infinity Pharmaceuticals, Inc., Novartis AG Sponsored ADR, Mylan N.V., Lannett Company, Inc., Teva Pharmaceutical Industries Limited Sponsored ... Read more
(Read more...)
Neurocrine Biosciences Appoints Matt Abernethy as Chief Financial Officer Mon, 20 Nov 2017 21:01:00 +0000 SAN DIEGO, Nov. 20, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX), a biotechnology company focused on neurological and endocrine related disorders, today announced that Matt Abernethy is joining the executive management team as Chief Financial Officer (CFO). "We are very pleased to welcome Matt Abernethy to the Neurocrine team as our Chief Financial Officer," said Kevin Gorman, Ph.D., Chief Executive Officer of Neurocrine Biosciences. Abernethy has nearly 15 years of experience in the financial sector and investor relations with expertise in the healthcare industry. He joins Neurocrine from Zimmer Biomet, where he held various positions over the past nine years including Vice President, Investor Relations and Treasurer and Vice President of Finance for the Americas and Global Product Engines.
Neurocrine Announces Long-Term Results Evaluating INGREZZA® for the Treatment of Adults with Tardive Dyskinesia Published in the Journal of Clinical Psychiatry Tue, 14 Nov 2017 18:34:00 +0000 SAN DIEGO, Nov. 14, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) announced today that the full manuscript of the long-term safety and efficacy data from the blinded KINECT 3 Phase III extension study evaluating INGREZZA® (valbenazine) capsules for the treatment of adults with tardive dyskinesia (TD) were published in the Journal of Clinical Psychiatry1. The once-daily 80 mg and 40 mg doses of INGREZZA continued to maintain symptom improvement and were generally well-tolerated over long-term dosing in patients with TD, a condition characterized by uncontrollable, abnormal and repetitive movements of the trunk, extremities and/or face. "We are pleased with the long-term data, which demonstrate the ability of INGREZZA to effectively improve the symptoms of tardive dyskinesia with durable response," said Christopher O'Brien, M.D., Chief Medical Officer of Neurocrine Biosciences.
INGREZZA®, First FDA Approved Product for the Treatment of Tardive Dyskinesia, Receives Outstanding Therapeutic Product Award from Prestigious California Life Sciences Association Thu, 09 Nov 2017 21:01:00 +0000 SAN DIEGO, Nov. 9, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) announced today that INGREZZA® (valbenazine) capsules, the first FDA approved product indicated for the treatment of adults with tardive dyskinesia (TD), a condition characterized by uncontrollable, abnormal and repetitive movements of the trunk, extremities and/or face, was awarded the 2017 Pantheon DiNA Award for Outstanding Therapeutic Product by the California Life Sciences Association (CLSA). CLSA is the state's largest and most influential life sciences advocacy and business leadership organization. CLSA will honor this year's winners at the 2017 Pantheon DiNA Awards ceremony on Friday, November 10, at the Marriott Marquis in San Francisco.
Neurocrine to Present Data on the Patient Impact of Tardive Dyskinesia from the RE-KINECT Study at the 2017 Neuroscience Education Institute Congress Tue, 07 Nov 2017 21:01:00 +0000 SAN DIEGO, Nov. 7, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) today announced that data for INGREZZA® (valbenazine) capsules, the first FDA approved treatment for adults with tardive dyskinesia (TD), will be presented at the 2017 Neuroscience Education Institute Congress to be held November 8-12 in Colorado Springs, Colorado. Data being presented include analyses from the RE-KINECT study, a real-world screening study and registry that describes the presence and impact of involuntary movements in patients taking antipsychotics, as well as pooled data analyses from INGREZZA clinical studies across patient sub-groups. "We are pleased to share findings on the impact of tardive dyskinesia, which is characterized by uncontrollable, abnormal and repetitive movements, on real-world patients," said Chris O'Brien, M
See what the IHS Markit Score report has to say about Penumbra Inc. Wed, 22 Nov 2017 13:03:37 +0000 The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last month, ETFs holding PEN are favorable, with net inflows of $3.42 billion.
ETFs with exposure to Penumbra, Inc. : November 14, 2017 Tue, 14 Nov 2017 19:43:00 +0000 Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Penumbra, Inc. Here are 5 ETFs with the largest exposure to PEN-US. Comparing the performance and risk of Penumbra, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more
(Read more...)
Penumbra, Inc. :PEN-US: Earnings Analysis: Q3, 2017 By the Numbers : November 13, 2017 Mon, 13 Nov 2017 14:01:07 +0000 Categories: Yahoo FinanceGet free summary analysis Penumbra, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Penumbra, Inc. – NuVasive, Inc. (NUVA-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD 83.91 million, Net Earnings of USD 0.24 million. Gross margins ... Read more
(Read more...)
Should You Buy Penumbra Inc (PEN) Now? Fri, 10 Nov 2017 20:45:06 +0000 Penumbra Inc (NYSE:PEN), a healthcare equipment and supplies company based in United States, saw a significant share price rise of over 20% in the past couple of months on theRead More...
Penumbra, Inc. Reports Third Quarter 2017 Financial Results Tue, 07 Nov 2017 21:05:00 +0000 ALAMEDA, Calif. , Nov. 7, 2017 /PRNewswire/ -- Penumbra, Inc.(NYSE: PEN), a global healthcare company focused on interventional therapies, today reported financial results for the third quarter ended September 30, ...
Penumbra, Inc. to Host Earnings Call Tue, 07 Nov 2017 20:00:00 +0000 NEW YORK, NY / ACCESSWIRE / November 7, 2017 / Penumbra, Inc. (NYSE: PEN ) will be discussing their earnings results in their Q3 Earnings Call to be held on November 7, 2017 at 5:00 PM Eastern Time. To ...
We are Sarepta Therapeutics: a biopharmaceutical company focused on developing innovative RNA-targeted therapeutics. Our goal is to harness the power of cutting-edge technology to improve the lives of people affected by rare, infectious and other diseases.
Today’s Research Reports on Trending Tickers: Novavax and Sarepta Therapeutics Tue, 14 Nov 2017 13:10:00 +0000 NEW YORK, NY / ACCESSWIRE / November 14, 2017 / After posting its first weekly loss in two months on Friday, the Dow Jones and S&P 500 Index opened the week in the green on Monday. The Dow Jones Industrial ...
[$$] Sarepta: Too Much Good News to Ignore Fri, 10 Nov 2017 13:25:00 +0000 Sarepta Therapeutics (SRPT) has moved to solidify its position as the leading company in the treatment of Duchenne muscular dystrophy (DMD) with the recent announcement of three new clinical trials. Sarepta CEO Doug Ingram called the Anthem move “a fantastic result for children with DMD” in a Barron’s interview Thursday. The selloff probably reflects hedging activity by convertible arbitragers who purchased the big Sarepta convertible.
Health insurer Anthem eases restrictions on Sarepta's Duchenne treatment Thu, 09 Nov 2017 20:07:17 +0000 The U.S. Food and Drug Administration approved Sarepta for Duchenne, a degenerative disease that mostly affects young boys, last year despite questions from experts and its own reviewers about the efficacy of the drug. An Anthem spokeswoman said its medical policy committee had reviewed information presented at recent scientific meetings, feedback from clinicians and information from Sarepta before making the change. Sarepta Chief Executive Doug Ingram said the move was encouraging for children with the disease because it could loosen up strict policies at health insurers who have tight controls on covering the treatment.
Sarepta: Payers Gonna Pay? Thu, 09 Nov 2017 14:35:00 +0000 Sarepta Therapeutics (SRPT) got some good news today when health insurer Anthem (ANTM) decided to cover the treatment of Sarepta’s drug for Duchenne muscular dystrophy, Exondys 51, in ambulatory patients, ...
Sarepta Therapeutics Prices $475 Million of Convertible Senior Notes Due 2024 Wed, 08 Nov 2017 23:45:00 +0000 CAMBRIDGE, Mass., Nov. 08, 2017-- Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicines to treat rare neuromuscular ...
Xoma: A Lower Risk Way Of Investing In Biotech Fri, 10 Nov 2017 22:14:00 +0000 Biotech stocks have been big winners this year. But since they can lose 50% in a single day, readers have asked if there is a "safer" way to invest. Bruce Pile tells us about Ligand Pharmaceuticals and Xoma Corp., two biotechs that do not bet the whole company on a single drug candidate.
Xoma beats 3Q profit forecasts Mon, 06 Nov 2017 22:28:10 +0000 The Berkeley, California-based company said it had net income of $1.98 per share. The results topped Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...
XOMA to Present at the Cantor Fitzgerald Global Healthcare Conference Tue, 19 Sep 2017 11:00:00 +0000 BERKELEY, Calif., Sept. 19, 2017-- XOMA Corporation, a pioneer in the discovery, development and licensing of therapeutic antibodies, today announced that Jim Neal, Chief Executive Officer, will present ...
ETFs with exposure to XOMA Corp. : September 7, 2017 Thu, 07 Sep 2017 18:17:17 +0000 Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to XOMA Corp. Here are 5 ETFs with the largest exposure to XOMA-US. Comparing the performance and risk of XOMA Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more
(Read more...)
Today's Research Reports on Stocks to Watch: Insmed Inc. and XOMA Corporation Wed, 06 Sep 2017 12:10:00 +0000 NEW YORK, NY / ACCESSWIRE / September 6, 2017 / XOMA and Insmed both saw their shares blast off on Tuesday. XOMA gained nearly 44% after being upgraded by Wedbush on account of the company announcing that ...
[$$] Novartis Deal Could Send Xoma Stock to $19 Wed, 06 Sep 2017 11:20:00 +0000 Xoma (XOMA:Nasdaq) By Wedbush ($11.18, Sept. 5, 2017) We are upgrading our rating on Xoma to Outperform from Neutral and increasing our 12-month price target to $19 from $9. Due to clinical failures, we thought gevokizumab was shelved but recent cardiovascular clinical success with Novartis’ (NVS) canakinumab apparently created strategic value to have more than one anti-IL-1β treatment--prompting Novartis to license gevokizumab and anti-IL-1β. For gevokizumab, Xoma receives $16 million upfront cash and is eligible for up to $438 million in milestones and high single digit to mid-double-digit percentage tiered royalties on sales.
The Forbes Healthcare Summit: The Final Agenda Mon, 20 Nov 2017 15:12:00 +0000 Here we go. We're just weeks away from Forbes' annual Healthcare Summit. Get ready for a packed 24-hour experience.
ETFs with exposure to bluebird bio, Inc. : November 16, 2017 Thu, 16 Nov 2017 16:16:24 +0000 Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to bluebird bio, Inc. Here are 5 ETFs with the largest exposure to BLUE-US. Comparing the performance and risk of bluebird bio, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more
(Read more...)
3 Top Healthcare Stocks to Buy in November Mon, 13 Nov 2017 14:31:00 +0000 Healthcare stocks are some of the most intriguing long-term stocks to buy. Picking up these stars now could end up being very profit-friendly.
The Forbes Healthcare Summit 2017: The Draft Agenda Fri, 10 Nov 2017 18:30:00 +0000 The time is drawing near: our sixth annual Forbes Healthcare Summit will be held on Nov. 29 and Nov. 30. The event will take attendees through the whole spectrum of the healthcare business, from the cutting edge of gene therapy and to the hard economic choices every health system must make.
3 Stocks to Buy for a Better Tomorrow Mon, 06 Nov 2017 13:18:00 +0000 Investing in the stock market is one way to do well (financially) by doing good.
bluebird bio, Inc. :BLUE-US: Earnings Analysis: Q3, 2017 By the Numbers : November 3, 2017 Fri, 03 Nov 2017 14:08:07 +0000 Categories: Yahoo FinanceGet free summary analysis bluebird bio, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of bluebird bio, Inc. – Celgene Corporation, BioMarin Pharmaceutical Inc. and Merck & Co., Inc. (CELG-US, BMRN-US and MRK-US) that have also reported for this period. Highlights Summary numbers: ... Read more
(Read more...)
Ignyta to Present at the 29th Annual Piper Jaffray Healthcare Conference Wed, 22 Nov 2017 12:00:00 +0000 Ignyta, Inc. , a biotechnology company focused on precision medicine in oncology, announced today that Jonathan Lim, M.D., its Chairman and Chief Executive Officer, will make a presentation at the 29th Annual Piper Jaffray Healthcare Conference on November 29, 2017, at 11:00 a.m.
Ignyta Reports Granting of Inducement Awards Thu, 16 Nov 2017 12:00:00 +0000 Ignyta, Inc. , a biotechnology company focused on precision medicine in oncology, announced today that it has issued two inducement awards to new non-executive employees.
Ignyta to Present at the Jefferies 2017 London Healthcare Conference Thu, 09 Nov 2017 21:00:00 +0000 Ignyta, Inc. , a biotechnology company focused on precision medicine in oncology, announced today that Jacob Chacko, M.D., its Chief Financial Officer, will make a presentation at the Jefferies 2017 London Healthcare Conference on November 16, 2017, at 1:20 p.m.
Ignyta Announces New Data Highlighting Immune Modulation of RXDX-106 at the Society for Immunotherapy of Cancer (SITC) Meeting Wed, 08 Nov 2017 13:00:00 +0000 Ignyta, Inc. , a biotechnology company focused on precision medicine in oncology, today announced new preclinical data for RXDX-106 – a novel immunomodulatory agent that demonstrated potent anti-tumor activity, alone and in combination with checkpoint inhibitors, by modulating the tumor microenvironment through TYRO3, AXL, and MER receptor tyrosine kinase inhibition.
Ignyta reports 3Q loss Wed, 08 Nov 2017 00:51:53 +0000 On a per-share basis, the San Diego-based company said it had a loss of 51 cents. Ignyta shares have nearly tripled since the beginning of the year. In the final minutes of trading on Tuesday, shares hit ...
Ignyta to Present at Credit Suisse 26th Annual Healthcare Conference Wed, 01 Nov 2017 20:00:00 +0000 Ignyta, Inc. , a biotechnology company focused on precision medicine in oncology, announced today that Jacob Chacko, M.D., its Chief Financial Officer, will make a presentation at the Credit Suisse 26th Annual Healthcare Conference on Wednesday, November 8, 2017, at 11:35 a.m.
Ignyta Announces Pricing of Public Offering of Common Stock Fri, 20 Oct 2017 00:05:00 +0000 Ignyta, Inc. , a biotechnology company focused on precision medicine in oncology, today announced the pricing of an underwritten public offering of 10.0 million shares of its common stock at a price to the public of $16.00 per share.
Recro Pharma Secures $100 Million Credit Facility Mon, 20 Nov 2017 12:00:00 +0000 Proceeds Provide Funding for IV Meloxicam 30 mg Approval Milestone. Interest-only Structure Allows for Reinvestment of CDMO Cash Flows in Value Accretive Commercial Activities. Substantial Reduction in ...
Recro Pharma reports 3Q loss Thu, 09 Nov 2017 14:37:44 +0000 On a per-share basis, the Malvern, Pennsylvania-based company said it had a loss of 48 cents. The results surpassed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...
Recro Pharma Reports Third Quarter 2017 Financial Results Thu, 09 Nov 2017 12:00:00 +0000 NDA Submission for IV Meloxicam Accepted by U.S. FDA for Review; PDUFA Date Set for May 26, 2018. Strong Gainesville Manufacturing Performance; Third Quarter 2017 Revenues of $17.1 Million.
Recro Pharma to Present at Upcoming Investor Conferences Wed, 08 Nov 2017 12:00:00 +0000 MALVERN, Pa., Nov. 08, 2017-- Recro Pharma, Inc., a revenue generating specialty pharmaceutical company focused on therapeutics for hospital and other acute care settings, today announced that Gerri Henwood, ...
Recro Pharma Reports Inducement Grants for New Staff Tue, 31 Oct 2017 11:00:00 +0000 MALVERN, Pa., Oct. 31, 2017-- Recro Pharma, Inc., a revenue generating specialty pharmaceutical company focused on therapeutics for hospital and other acute care settings, today announced the expansion ...
ETFs with exposure to Recro Pharma, Inc. : October 9, 2017 Mon, 09 Oct 2017 15:59:06 +0000 Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Recro Pharma, Inc. Here are 5 ETFs with the largest exposure to REPH-US. Comparing the performance and risk of Recro Pharma, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more
(Read more...)
Recro Pharma, Inc. :REPH-US: Earnings Analysis: Q2, 2017 By the Numbers : October 6, 2017 Fri, 06 Oct 2017 13:12:02 +0000 Categories: Yahoo FinanceGet free summary analysis Recro Pharma, Inc. reports financial results for the quarter ended June 30, 2017. Highlights Summary numbers: Revenues of USD 16.93 million, Net Earnings of USD -8.86 million. Gross margins narrowed from 41.01% to 34.49% compared to the same period last year, operating (EBITDA) margins now -33.55% from -12.22%. Change in operating ... Read more
(Read more...)
Recro Pharma to Participate in Upcoming Investor Conferences Thu, 05 Oct 2017 21:00:00 +0000 MALVERN, Pa., Oct. 05, 2017-- Recro Pharma, Inc., a revenue generating specialty pharmaceutical company focused on therapeutics for hospital and other acute care settings, today announced that Gerri Henwood, ...
Recro Pharma Announces PDUFA Date for IV Meloxicam 30mg Thu, 05 Oct 2017 11:00:00 +0000 MALVERN, Pa., Oct. 05, 2017-- Recro Pharma, Inc., a revenue generating specialty pharmaceutical company focused on therapeutics for hospital and other acute care settings, today announced that the U.S. ...
Who Are The Top Investors In Sangamo Therapeutics Inc (SGMO)? Fri, 24 Nov 2017 19:35:11 +0000 In this article, I will take a quick look at Sangamo Therapeutics Inc’s (NASDAQ:SGMO) recent ownership structure – an unconventional investing subject, but an important one. Ownership structure has beenRead More...
Sangamo Therapeutics, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Fri, 24 Nov 2017 18:01:00 +0000 RICHMOND, Calif., Nov. 24, 2017 /PRNewswire/ -- Sangamo Therapeutics, Inc. (SGMO) announced today that the Compensation Committee of the Company's Board of Directors approved the grant effective on November 22, 2017 of inducement stock options to purchase a total of 164,000 shares of common stock to four new employees. The stock options have an exercise price per share equal to $15.00, the fair market value on the grant date, November 22, 2017. Each stock option vests over the course of four years, with 25% vesting on the one-year anniversary of the grant date and 1/48 of the shares vesting monthly thereafter so that all of the shares subject to the stock option shall be vested on the fourth anniversary of the grant date, subject to the new employee's continued service relationship with the Company on each such date.
ETFs with exposure to Sangamo Therapeutics, Inc. : November 21, 2017 Tue, 21 Nov 2017 17:12:12 +0000 Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Sangamo Therapeutics, Inc. Here are 5 ETFs with the largest exposure to SGMO-US. Comparing the performance and risk of Sangamo Therapeutics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more
(Read more...)
Sangamo Therapeutics, Inc. – Value Analysis (NASDAQ:SGMO) : November 17, 2017 Fri, 17 Nov 2017 18:55:26 +0000 Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Sangamo Therapeutics, Inc. a score of 14. Our analysis is based on comparing Sangamo Therapeutics, Inc. with the following peers – Alnylam Pharmaceuticals, Inc, Gilead Sciences, Inc., Amgen Inc., Merck & Co., Inc., BioMarin Pharmaceutical Inc., Johnson & Johnson, DowDuPont Inc., Shire PLC Sponsored ADR, Biogen Inc. ... Read more
(Read more...)
Sangamo Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : SGMO-US : November 16, 2017 Thu, 16 Nov 2017 12:06:03 +0000 Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Sangamo Therapeutics, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish ... Read more
(Read more...)
Sangamo Announces Treatment of First Patient in Landmark Phase 1/2 Clinical Trial Evaluating In Vivo Genome Editing for MPS II Wed, 15 Nov 2017 06:10:00 +0000 RICHMOND, Calif., Nov. 15, 2017 /PRNewswire/ -- Sangamo Therapeutics, Inc. (SGMO) today announced treatment of the first patient in the Phase 1/2 clinical trial ("the CHAMPIONS study") evaluating SB-913, an investigational in vivo genome editing therapy for people with mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome. Sangamo aims to treat MPS II by using genome editing to insert a corrective gene into a precise location in the DNA of liver cells with the goal of enabling a patient's liver to produce a lifelong and stable supply of an enzyme he or she currently lacks. Without that enzyme, called iduronate-2-sulfatase (IDS), people with MPS II suffer debilitating buildup of toxic carbohydrates in cells throughout their body.
Is It Time To Buy Trillium Therapeutics Inc (TRIL)? Wed, 15 Nov 2017 15:17:09 +0000 Trillium Therapeutics Inc (NASDAQ:TRIL), a biotechnology company based in Canada, led the NasdaqCM gainers with a relatively large price hike in the past couple of weeks. As a stock withRead More...
Trillium Announces Private Placement Wed, 15 Nov 2017 14:15:00 +0000 Trillium Therapeutics Inc. , a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has entered into subscription agreements for the ...
Trillium Therapeutics Reports Third Quarter 2017 Financial and Operating Results Fri, 10 Nov 2017 12:00:00 +0000 Trillium Therapeutics Inc. , a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today reported financial results for the nine months ended September 30, ...
Trillium Therapeutics to Present at Upcoming Scientific Conferences Mon, 06 Nov 2017 12:00:00 +0000 Trillium Therapeutics Inc. a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that the company is scheduled to present an update on the ...
ETFs with exposure to CytomX Therapeutics, Inc. : November 20, 2017 Mon, 20 Nov 2017 17:07:23 +0000 Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to CytomX Therapeutics, Inc. Here are 5 ETFs with the largest exposure to CTMX-US. Comparing the performance and risk of CytomX Therapeutics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more
(Read more...)
CytomX Therapeutics, Inc. :CTMX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 13, 2017 Mon, 13 Nov 2017 13:43:05 +0000 Categories: Yahoo FinanceGet free summary analysis CytomX Therapeutics, Inc. reports financial results for the quarter ended September 30, 2017. Highlights Summary numbers: Revenues of USD 24.14 million, Net Earnings of USD -10.25 million. Change in operating cash flow of 59.54% compared to same period last year is about the same as change in earnings, likely no significant ... Read more
(Read more...)
CytomX Therapeutics reports 3Q loss Wed, 08 Nov 2017 00:03:36 +0000 The South San Francisco, California-based company said it had a loss of 28 cents per share. The results missed Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment ...
CytomX to Present at the Jefferies 2017 London Healthcare Conference Wed, 01 Nov 2017 20:05:00 +0000 SOUTH SAN FRANCISCO, Calif., Nov. 01, 2017-- CytomX Therapeutics, Inc., a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, will present at the Jefferies ...
CytomX Therapeutics to Announce Third Quarter 2017 Financial Results Thu, 26 Oct 2017 20:26:17 +0000 SOUTH SAN FRANCISCO, Calif., Oct. 26, 2017-- CytomX Therapeutics, Inc., a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, will announce financial ...
Cancer Space Last Week Update: Pipeline Expansion in Focus Mon, 09 Oct 2017 14:13:02 +0000 Last week, a few companies in the cancer segment entered deals for expanding their portfolio. Another key development was a ruling in favor of a major cancer drug by the U.S. patent office.
Analysts’ Recommendations for Amgen in October 2017 Mon, 09 Oct 2017 11:44:10 +0000 Of the 24 analysts tracking Amgen (AMGN) in October 2017, ~42% of the analysts recommended a “buy” rating, and the rest suggested a ”hold.” On October 5, Amgen had a consensus 12-month target price of ...
Aimmune Therapeutics reports 3Q loss Mon, 06 Nov 2017 13:37:31 +0000 On a per-share basis, the Brisbane, California-based company said it had a loss of 63 cents. The results beat Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...
Aimmune Therapeutics to Participate in Four Investor Conferences in November Wed, 01 Nov 2017 12:00:00 +0000 Aimmune Therapeutics, Inc. , a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that members of the Aimmune executive management team will participate in four upcoming investor conferences in November.
DBV Technologies’ Pain is Aimmune Therapeutics Inc’s (AIMT) Gain Mon, 23 Oct 2017 17:46:27 +0000 It's a very rewarding trading day for Aimmune Therapeutics Inc (NASDAQ:AIMT) investors with shares up over 30%, making the stock Wall Street's bull of the day. The reason? The allergy medicine maker benefited from the news that its competitor DBV Technologies SA - ADR (NASDAQ:DBVT) reported disappointing late-stage clinical trial results for its experimental treatment, Viaskin Peanut, a patch designed to enhance protection of peanut allergic children.
DBV Shares Fall After Phase 3 Data on Peanut Allergy Treatment -- Biotech Movers Mon, 23 Oct 2017 13:15:00 +0000 The Montrouge, France-based firm on Friday unveiled top-line results from its Phase 3 study of a peanut allergy treatment. The study, dubbed Pepites, evaluated Viaskin Peanut in children four to 11 years ...
REGENXBIO is leveraging its proprietary NAV® Technology and collaborating with world-class clinical advisors to advance the development of life-changing gene therapy treatments for lysosomal storage disorders and ocular diseases.
REGENXBIO to Present at Upcoming Investor Conferences Wed, 22 Nov 2017 12:00:00 +0000 ROCKVILLE, Md., Nov. 22, 2017-- REGENXBIO Inc., a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV ® Technology ...
Regenxbio reports 3Q loss Wed, 08 Nov 2017 22:33:58 +0000 The Rockville, Maryland-based company said it had a loss of 67 cents per share. The biotechnology company posted revenue of $1.3 million in the period. Regenxbio shares have climbed 42 percent since the ...
REGENXBIO, Inc. breached its 50 day moving average in a Bearish Manner : RGNX-US : November 2, 2017 Thu, 02 Nov 2017 12:31:01 +0000 Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for REGENXBIO, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bullish 50 ... Read more
(Read more...)
ETFs with exposure to REGENXBIO, Inc. : October 30, 2017 Mon, 30 Oct 2017 16:12:44 +0000 Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to REGENXBIO, Inc. Here are 5 ETFs with the largest exposure to RGNX-US. Comparing the performance and risk of REGENXBIO, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more
(Read more...)
Gene Therapies: A Foot in the Door Fri, 13 Oct 2017 16:31:00 +0000 The yes vote by the FDA advisory panel for Spark Therapeutics’ (ONCE) drug Luxturna has opened the door for gene therapies at the FDA. Leerink’s Joseph Schwartz weighed in on that very topic today. Proclaiming it “a new era for gene therapy,” he says the results of yesterday’s vote is a “momentous advance” for the drug category that suggests that the public’s and regulators’ long-standing caution is “at an inflection point.” If the FDA follows-through on today's unanimous vote and approves Luxturna by Jan 12, 2018, we believe the tailwind could benefit companies like Audentes (BOLD [OP]), BioMarin (BMRN [OP]), REGENXBIO (RGNX [NR]), uniQure (QURE [OP]) and Ultragenyx (RARE [OP]) post-DMTX acquisition.
REGENXBIO, Inc. :RGNX-US: Earnings Analysis: Q2, 2017 By the Numbers : October 6, 2017 Fri, 06 Oct 2017 13:09:07 +0000 Categories: Yahoo FinanceGet free summary analysis REGENXBIO, Inc. reports financial results for the quarter ended June 30, 2017. Highlights Summary numbers: Revenues of USD 6.56 million, Net Earnings of USD -14.47 million. Gross margins widened from 79.03% to 79.93% compared to the same period last year, operating (EBITDA) margins now -218.73% from -628.04%. Change in operating cash ... Read more
(Read more...)
uniQure NV :QURE-US: Earnings Analysis: Q3, 2017 By the Numbers : November 7, 2017 Tue, 07 Nov 2017 13:07:39 +0000 Categories: Yahoo FinanceGet free summary analysis uniQure NV reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of uniQure NV – Amgen Inc., bluebird bio, Inc. and BioMarin Pharmaceutical Inc. (AMGN-US, BLUE-US and BMRN-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD ... Read more
(Read more...)
UniQure reports 3Q loss Wed, 01 Nov 2017 11:17:30 +0000 On a per-share basis, the Amsterdam-based company said it had a loss of 40 cents. The results exceeded Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...
uniQure Announces Pricing of its Public Offering Wed, 25 Oct 2017 00:14:48 +0000 LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Oct. 24, 2017-- uniQure N.V., a leading gene therapy company advancing transformative therapies for patients with severe unmet medical needs, such as hemophilia ...
uniQure Announces Proposed Public Offering Mon, 23 Oct 2017 20:06:28 +0000 LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Oct. 23, 2017-- uniQure N.V., a leading gene therapy company advancing transformative therapies for patients with severe unmet medical needs, such as hemophilia ...
Why uniQure N.V. Stock Is Hopping Today Fri, 20 Oct 2017 19:00:00 +0000 Investors are cheering the FDA's surprisingly progressive take on uniQure's novel hemophilia B gene therapy candidate.
Cowen Shines Light on Uniqure NV (QURE) as the Latter Advances Padua Variant AMT-061 into Phase 3 Thu, 19 Oct 2017 19:28:30 +0000 Uniqure NV (NASDAQ:QURE) investors are overwhelmingly excited today after the drug maker announced advancement of AMT-061, a Padua variant FIX AAV5 gene therapy, in hemophilia B, into a pivotal phase 3 trial in 3Q18. Cowen analyst Ritu Baral commented, "Surprisingly to us, this payload change (Padua FIX variant has a 2 nucleotide change leading to a single amino acid substitution) will be allowed to start clinical trials under the same IND and maintain FDA Breakthrough Designation and EMA PRIME Designation granted to AMT-060. "We do note other than the 2 nucleotide substitution, AMT-060 and AMT-061 are otherwise structurally identical, which we find encouraging given the predictability and duration of response seen with AMT-060 as well as excellent safety and low population seropositivity to date.
Concert posts 3Q profit Thu, 09 Nov 2017 15:50:48 +0000 On a per-share basis, the Lexington, Massachusetts-based company said it had net income of $5.44. Losses, adjusted for non-recurring gains, came to 70 cents per share. The biopharmaceutical company posted ...
Concert Pharmaceuticals, Inc. to Host Earnings Call Thu, 09 Nov 2017 13:23:00 +0000 NEW YORK, NY / ACCESSWIRE / November 9, 2017 / Concert Pharmaceuticals, Inc. (NASDAQ: CNCE ) will be discussing their earnings results in their Q3 Earnings Call to be held on November 9, 2017 at 8:30 AM ...
Is It The Right Time To Buy Concert Pharmaceuticals Inc (CNCE)? Mon, 06 Nov 2017 13:52:10 +0000 Concert Pharmaceuticals Inc (NASDAQ:CNCE), a biotechnology company based in United States, led the NasdaqGM gainers with a relatively large price hike in the past couple of weeks. With many analystsRead More...
Concert Pharmaceuticals Announces Completion of Enrollment in First Cohort of CTP-543 Phase 2a Trial Mon, 06 Nov 2017 12:00:00 +0000 Concert Pharmaceuticals, Inc. today announced that it has completed enrollment of the first cohort of its Phase 2a trial evaluating CTP-543. Concert is developing CTP-543 for the treatment of moderate-to-severe alopecia areata, an autoimmune disorder in which the immune system attacks hair follicles, resulting in patchy or complete hair loss.
Concert Pharmaceuticals, Inc. – Value Analysis (NASDAQ:CNCE) : October 17, 2017 Tue, 17 Oct 2017 14:10:34 +0000 Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Concert Pharmaceuticals, Inc. a score of 14. Our analysis is based on comparing Concert Pharmaceuticals, Inc. with the following peers – Celgene Corporation, Jazz Pharmaceuticals Plc, Ardelyx, Inc., AbbVie, Inc., GW Pharmaceuticals PLC Sponsored ADR, Ionis Pharmaceuticals, Inc. and Trevena, Inc. (CELG-US, JAZZ-US, ARDX-US, ABBV-US, GWPH-US, IONS-US ... Read more
(Read more...)
Concert Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : CNCE-US : October 16, 2017 Mon, 16 Oct 2017 12:33:01 +0000 Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Concert Pharmaceuticals, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bullish ... Read more
(Read more...)
Should You Buy Emergent BioSolutions Inc (EBS) At This PE Ratio? Fri, 24 Nov 2017 21:55:16 +0000 Emergent BioSolutions Inc (NYSE:EBS) is currently trading at a trailing P/E of 20.6x, which is lower than the industry average of 26.9x. While EBS might seem like an attractive stockRead More...
Emergent BioSolutions, Inc. breached its 50 day moving average in a Bullish Manner : EBS-US : November 23, 2017 Thu, 23 Nov 2017 12:16:34 +0000 Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Emergent BioSolutions, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish ... Read more
(Read more...)
Perrigo (PRGO) Q3 Earnings Top, 2017 View Raised, Shares Up Thu, 09 Nov 2017 17:39:05 +0000 Perrigo (PRGO) posts better-than-expected earnings with revenues also beating estimates. The company ups its guidance, courtesy of a continued positive execution across all business segments.
ETFs with exposure to Emergent BioSolutions, Inc. : November 8, 2017 Wed, 08 Nov 2017 22:59:50 +0000 Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Emergent BioSolutions, Inc. Here are 5 ETFs with the largest exposure to EBS-US. Comparing the performance and risk of Emergent BioSolutions, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more
(Read more...)
Jazz Pharmaceuticals (JAZZ) Q3 Earnings Top, 2017 View Cut Wed, 08 Nov 2017 17:21:05 +0000 Jazz Pharmaceuticals (JAZZ) earnings beat estimates while revenues miss the same in Q3. The company also cuts its guidance due to lower-than-expected sales from Xyrem.
Arena Pharmaceuticals (ARNA) Q3 Loss Widens Y/Y, Sales Beat Wed, 08 Nov 2017 14:53:02 +0000 Arena Pharmaceuticals (ARNA) reports another quarter of lackluster Belviq sales. However, the company is likely to advance ralinepag in phase III study based on positive data from the previous stage.
ETFs with exposure to Juno Therapeutics, Inc. : November 17, 2017 Fri, 17 Nov 2017 17:12:56 +0000 Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Juno Therapeutics, Inc. Here are 5 ETFs with the largest exposure to JUNO-US. Comparing the performance and risk of Juno Therapeutics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more
(Read more...)
3 Top Biotech Stocks for 2018 Sun, 12 Nov 2017 13:00:00 +0000 Celgene Corp., Juno Therapeutics, and Cara Therapeutics are three biotech stocks to watch in 2018.
Juno Therapeutics to Present at November 2017 Investor Conferences Mon, 06 Nov 2017 21:05:00 +0000 Juno Therapeutics, Inc. today announced that it will webcast its presentations at two investor conferences in November. The presentations will feature a business overview and update by Steve Harr, Juno’s Chief Financial Officer and Head of Corporate Development.
Puma Biotechnology, Inc is a development stage biopharmaceutical company dedicated to in-licensing and developing novel therapeutics for the treatment of cancer. Puma Biotechnology is founded by Alan H. Auerbach, who previously served as Founder, Chief Executive Officer and President of Cougar Biotechnology, Inc, a company dedicated to in-licensing and developing drugs for the treatment of cancer. Cougar was acquired by Johnson & Johnson in July 2009 for approximately $1 billion.
Puma Inks License Deal to Commercialize Cancer Drug Nerlynx Thu, 23 Nov 2017 13:42:01 +0000 Puma (PBYI) signs a licensing deal with Specialised Therapeutics Asia to commercialize its breast cancer drug Nerlynx in Australia, New Zealand and South East Asia.
Should You Worry About Puma Biotechnology Inc’s (PBYI) CEO Salary Level? Fri, 10 Nov 2017 19:25:07 +0000 Alan Auerbach took the helm as Puma Biotechnology Inc’s (NASDAQ:PBYI) CEO and grew market cap to USD$4.77B recently. Recognizing whether CEO incentives are aligned with shareholders is a crucial partRead More...
Alnylam Pharmaceuticals, a leader in RNAi therapeutics, is a biopharmaceutical company developing novel therapeutics based on a breakthrough in biology known as RNA interference (RNAi).
Why is Alnylam's (ALNY) Stock Up More Than 200% this Year? Thu, 16 Nov 2017 15:59:03 +0000 Alnylam (ALNY) expects to achieve the profile of three marketed products by the end of 2020 and remains focused on development of its pipeline candidates.
Stemline Therapeutics reports 3Q loss Thu, 09 Nov 2017 22:14:01 +0000 The New York-based company said it had a loss of 68 cents per share. The results missed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a ...
Stemline Therapeutics Reports Third Quarter 2017 Financial Results Thu, 09 Nov 2017 21:01:00 +0000 NEW YORK, Nov. 09, 2017-- Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers, announced today financial results for the ...
Stemline Announces Four SL-401 Presentations at Upcoming ASH Meeting Wed, 01 Nov 2017 13:02:00 +0000 NEW YORK, Nov. 01, 2017-- Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers, announced today that SL-401, a novel targeted ...
Stemline Therapeutics to Present at Upcoming Investor Conferences Wed, 20 Sep 2017 11:00:00 +0000 NEW YORK, Sept. 20, 2017-- Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers, announced that Ivan Bergstein, M.D., Stemline’ ...
Stemline Therapeutics Presents SL-801 Phase 1 Data at ESMO 2017 Mon, 11 Sep 2017 11:00:00 +0000 NEW YORK, Sept. 11, 2017-- Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers, announced the presentation of clinical data ...
ETFs with exposure to Stemline Therapeutics, Inc. : September 1, 2017 Fri, 01 Sep 2017 01:14:58 +0000 Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Stemline Therapeutics, Inc. Here are 5 ETFs with the largest exposure to STML-US. Comparing the performance and risk of Stemline Therapeutics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more
(Read more...)
Stemline Therapeutics to Present SL-801 Phase 1 Data at Upcoming ESMO Congress Wed, 30 Aug 2017 22:10:00 +0000 NEW YORK, Aug. 30, 2017-- Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers, announced today that data from SL-801’ s ...
See what the IHS Markit Score report has to say about Illumina Inc. Fri, 24 Nov 2017 13:02:24 +0000 The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
Illumina to Webcast Upcoming Investor Conference Presentation Wed, 22 Nov 2017 14:00:00 +0000 Illumina, Inc. today announced that its executives will be speaking at the following investor conference, and invites investors to participate via webcast.
ETFs with exposure to Illumina, Inc. : November 20, 2017 Mon, 20 Nov 2017 17:41:35 +0000 Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Illumina, Inc. Here are 5 ETFs with the largest exposure to ILMN-US. Comparing the performance and risk of Illumina, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more
(Read more...)
Illumina, Inc. breached its 50 day moving average in a Bearish Manner : ILMN-US : November 15, 2017 Wed, 15 Nov 2017 12:52:01 +0000 Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Illumina, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bullish 50 ... Read more
(Read more...)
At Insmed we are on a mission to transform the lives of patients battling serious rare diseases. We are developing novel, targeted therapies to help serve the critical unmet needs of these patients. In concert with developing therapeutic solutions, we are committed to improving the entire patient experience, from diagnosis and treatment to everyday living.
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Wed, 22 Nov 2017 21:30:00 +0000 BRIDGEWATER, N.J., Nov. 22, 2017-- Insmed Incorporated, a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced the granting of inducement awards to ...
See what the IHS Markit Score report has to say about Insmed Inc. Wed, 22 Nov 2017 13:02:21 +0000 The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
3 Companies Spearheading the Antibiotics Space in 2018 Fri, 10 Nov 2017 16:15:32 +0000 Thanks to progress made in 2017 though, it looks like 2018 could see both a radically new way of delivering antibiotics and finally the first new class approved in 30 years. Here are three companies involved ...
Insmed to Present at Two November Conferences Wed, 08 Nov 2017 21:30:00 +0000 BRIDGEWATER, N.J., Nov. 08, 2017-- Insmed Incorporated, a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced that Will Lewis, President and Chief ...
Insmed reports 3Q loss Thu, 02 Nov 2017 12:03:42 +0000 On a per-share basis, the Bridgewater, New Jersey-based company said it had a loss of 69 cents. The results matched Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...
Insmed Reports Third Quarter 2017 Financial Results and Provides Business Update Thu, 02 Nov 2017 11:30:00 +0000 During the third quarter, the Company announced positive top-line results from its Phase 3 CONVERT Study of ALIS in patients with NTM lung disease caused by MAC, a rare, progressive, destructive lung infection ...
Insmed Incorporated to Host Earnings Call Thu, 02 Nov 2017 10:20:00 +0000 NEW YORK, NY / ACCESSWIRE / November 2, 2017 / Insmed Incorporated (NASDAQ: INSM ) will be discussing their earnings results in their Q3 Earnings Call to be held on November 2, 2017 at 8:30 AM Eastern ...
ETFs with exposure to FibroGen, Inc. : November 20, 2017 Mon, 20 Nov 2017 17:27:48 +0000 Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to FibroGen, Inc. Here are 5 ETFs with the largest exposure to FGEN-US. Comparing the performance and risk of FibroGen, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more
(Read more...)
See what the IHS Markit Score report has to say about FibroGen Inc. Wed, 15 Nov 2017 13:07:04 +0000 Short interest is low for FGEN with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last month, ETFs holding FGEN are favorable, with net inflows of $3.46 billion.
FibroGen, Inc. :FGEN-US: Earnings Analysis: Q3, 2017 By the Numbers : November 13, 2017 Mon, 13 Nov 2017 14:34:22 +0000 Categories: Yahoo FinanceGet free summary analysis FibroGen, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of FibroGen, Inc. – Illumina, Inc., Acceleron Pharma Inc, Accelerate Diagnostics, Inc. and Harvard Bioscience, Inc. (ILMN-US, XLRN-US, AXDX-US and HBIO-US) that have also reported for this period. Highlights Summary ... Read more
(Read more...)
FibroGen, Inc. breached its 50 day moving average in a Bearish Manner : FGEN-US : November 10, 2017 Fri, 10 Nov 2017 12:58:22 +0000 Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for FibroGen, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bullish 50 ... Read more
(Read more...)
FibroGen reports 3Q loss Wed, 08 Nov 2017 22:31:59 +0000 The San Francisco-based company said it had a loss of 50 cents per share. The results missed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for ...
FibroGen Reports Third Quarter 2017 Financial Results Wed, 08 Nov 2017 21:02:00 +0000 Roxadustat NDA Filing Accepted for CFDA Review; Positive Pamrevlumab Phase 2 IPF Results Reported Conference Call and Webcast to be Held Today at 5:00 p.m. Eastern Time/2: 00 p.m. SAN FRANCISCO, Nov. 08, ...
FibroGen, Inc. to Host Earnings Call Wed, 08 Nov 2017 19:10:00 +0000 NEW YORK, NY / ACCESSWIRE / November 8, 2017 / FibroGen, Inc. (NASDAQ: FGEN ) will be discussing their earnings results in their Q3 Earnings Call to be held on November 8, 2017 at 5:00 PM Eastern Time. ...
Dicerna to Present at the Evercore ISI Biopharma Catalyst/Deep Dive Conference Tue, 21 Nov 2017 12:30:00 +0000 Dicerna Pharmaceuticals, Inc. , a leading developer of investigational ribonucleic acid interference therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will present at the inaugural Evercore ISI Biopharma Catalyst/Deep Dive Conference on Thursday, November 30, 2017 at 1:35 p.m.
ETFs with exposure to Dicerna Pharmaceuticals, Inc. : November 8, 2017 Wed, 08 Nov 2017 22:57:44 +0000 Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Dicerna Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to DRNA-US. Comparing the performance and risk of Dicerna Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more
(Read more...)
Dicerna to Present at the Stifel 2017 Healthcare Conference Wed, 08 Nov 2017 12:30:00 +0000 Dicerna Pharmaceuticals, Inc. , a leading developer of investigational ribonucleic acid interference therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will present at the Stifel 2017 Healthcare Conference on Wednesday, November 15, 2017 at 2:45 p.m.
Dicerna Pharmaceuticals, Inc. :DRNA-US: Earnings Analysis: Q3, 2017 By the Numbers : November 7, 2017 Tue, 07 Nov 2017 13:05:26 +0000 Categories: Yahoo FinanceGet free summary analysis Dicerna Pharmaceuticals, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Dicerna Pharmaceuticals, Inc. – Pfizer Inc., Merck & Co., Inc. and Amgen Inc. (PFE-US, MRK-US and AMGN-US) that have also reported for this period. Highlights Summary numbers: Revenues ... Read more
(Read more...)
Dicerna Pharmaceuticals posts 3Q loss Thu, 02 Nov 2017 22:27:35 +0000 The Cambridge, Massachusetts-based company said it had a loss of 92 cents per share. The results missed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...
Dicerna Pharmaceuticals, Inc. to Host Earnings Call Thu, 02 Nov 2017 16:20:00 +0000 NEW YORK, NY / ACCESSWIRE / November 2, 2017 / Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA ) will be discussing their earnings results in their Q3 Earnings Call to be held on November 2, 2017 at 4:30 PM ...
GTx reports 3Q loss Thu, 16 Nov 2017 10:14:40 +0000 On a per-share basis, the Memphis, Tennessee-based company said it had a loss of 53 cents. GTx shares have more than doubled since the beginning of the year. The stock has climbed 42 percent in the last ...
GTx, Inc. to Participate in the Stifel 2017 Healthcare Conference Wed, 08 Nov 2017 12:30:00 +0000 GTx, Inc. today announced that Robert J. Wills, PhD, Executive Chairman, will present a company overview at the Stifel 2017 Healthcare Conference on Wednesday, November 15, 2017 at 9:30 am EST.
GTx Announces Closing of $48.5 Million Private Placement Fri, 29 Sep 2017 20:05:00 +0000 GTx, Inc. today announced that it has closed the previously-announced private placement of its common stock and warrants to purchase its common stock. In the private placement, GTx sold 5,483,320 immediately separable units, comprised of an aggregate of 5,483,320 newly-issued shares of common stock and warrants to purchase up to 3,289,988 additional shares of common stock, for an aggregate purchase ...
GTx Announces $48.5 Million Private Placement Tue, 26 Sep 2017 11:30:00 +0000 GTx, Inc. today announced that it has entered into a definitive securities purchase agreement for the sale of its common stock and warrants to purchase common stock in a private placement that is expected to result in gross proceeds to the Company of approximately $48.5 million, before deducting placement agent and other offering expenses.
GTx's (GTXI) Enobosarm Positive in Phase II, Shares Down Thu, 14 Sep 2017 21:50:09 +0000 GTx (GTXI) posts positive data from a phase II study of enobosarm for treating women with stress urinary incontinence. However, shares dip possibly with the release falling below market estimates.
At CymaBay, we are committed to improving the lives of patients with liver and other chronic diseases by developing and providing access to innovative therapies.
We are dedicated to enhancing the quality of healthcare by addressing the complex needs of patients, caregivers and communities and advancing medical knowledge.
CymaBay Therapeutics to Present at Three Investor Conferences Mon, 13 Nov 2017 13:00:00 +0000 NEWARK, Calif., Nov. 13, 2017-- CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced ...
CymaBay Reports Third Quarter 2017 Financial Results and Corporate Updates Wed, 08 Nov 2017 21:01:00 +0000 NEWARK, Calif., Nov. 08, 2017-- CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced ...
CymaBay Therapeutics, Inc. to Host Earnings Call Wed, 08 Nov 2017 18:00:00 +0000 NEW YORK, NY / ACCESSWIRE / November 8, 2017 / CymaBay Therapeutics, Inc. (NASDAQ: CBAY ) will be discussing their earnings results in their Q3 Earnings Call to be held on November 8, 2017 at 4:30 PM Eastern ...
CymaBay to Report Third Quarter 2017 Financial Results on Wednesday, November 8 Wed, 01 Nov 2017 12:30:00 +0000 NEWARK, Calif., Nov. 01, 2017-- CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced ...
CymaBay Therapeutics to Present at Two Investor Conferences Mon, 18 Sep 2017 12:00:00 +0000 NEWARK, Calif., Sept. 18, 2017-- CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need, ...
Intercept Pharmaceuticals Inc (ICPT) Stock Dives on Drug Warning Tue, 12 Sep 2017 16:50:03 +0000 The drug warning that sent ICPT stock down on Tuesday came in the form of a letter sent to physicians. In the letter concerning Ocaliva, Intercept Pharmaceuticals Inc notes that there have been connections between overdosing on the drug and certain liver issues. “Today’s letter/disclosure, in our view, will likely add another layer of caution as physicians may find Ocaliva dosing more cumbersome and patients more reluctant to initiate therapy,” Joseph Schwartz, a Leerink analyst, said in a statement obtained by Investor’s Business Daily.
Oramed is a biotechnology company focused on the commercial development of proprietrary oral delivery solutation. Currently, Oramed's leading product is the treatment of diabetes via an oral insulin capsule.
Oramed Receives Regulatory Approval to Conduct Clinical Study for Treatment of NASH with its Oral Insulin Capsule Tue, 14 Nov 2017 13:00:00 +0000 "Data from our directed preclinical NASH studies and clinical studies of ORMD-0801 in diabetics has revealed, through exploratory endpoints, that our oral insulin capsule has the ability to reduce inflammation of the liver. Incidence of NASH is rapidly increasing, similar to the rates of increase in diabetes. We look forward to exploring ORMD-0801 as a potential treatment for NASH," stated Oramed CEO, Nadav Kidron.
Oramed Granted Broad Composition of Matter Patent in Europe for Oral Proteins Tue, 31 Oct 2017 12:35:00 +0000 JERUSALEM, Oct. 31, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ/TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today the European Patent Office has issued to Oramed a notice of intent to grant a patent for broader claims for its invention titled, 'Methods and Compositions for Oral Administration of Proteins'. The patent covers Oramed's drugs including its oral insulin capsule ORMD-0801 which is currently in clinical development for type 1 and type 2 diabetes, as well as ORMD-0901, an oral GLP-1 analog capsule. Oramed's invention is designed to prevent the breakdown of protein-based drugs in the gastrointestinal track and promotes its crossing the small intestine.
Oramed to Present at the Diabetes Technology Meeting Tue, 24 Oct 2017 13:25:00 +0000 JERUSALEM , October 24, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ/TASE: ORMP) ( http://www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery ...
Oramed to Present at the Disruptive Growth Showcase Conference Mon, 25 Sep 2017 12:55:00 +0000 JERUSALEM , Sept. 25, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ/TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, ...
Oramed (ORMP): Successful Meeting with FDA for Oral Insulin Tue, 05 Sep 2017 13:00:00 +0000 By Grant Zeng, CFA NASDAQ:ORMP The FDA Meeting Earlier today (Sept. 5, 2017), Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) announced that it has successfully concluded a meeting with the US FDA regarding ...
Oramed Announces Successful Meeting with FDA for Oral Insulin Tue, 05 Sep 2017 10:00:00 +0000 JERUSALEM, Sept. 5, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (ORMP) (ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has successfully concluded its meeting with the U.S. Food and Drug Administration (FDA) regarding ORMD-0801, the Company's novel oral insulin formulation. At the meeting, the FDA gave clear guidance that the regulatory pathway for submission of ORMD-0801, would be a Biologics License Application (BLA). Such a pathway would grant a full 12 years of marketing exclusivity for ORMD-0801 if approved. On top of this, an additional six months of exclusivity can be granted if the product also receives approval for use in pediatric patients. The FDA confirmed that the approach to nonclinical toxicology, CMC and qualification of excipients would be driven by their published guidance documents, consistent with the Company's expectations. They also made specific recommendations for clinical trials designed to provide pivotal data prior to registration.
Oramed to Present at the Rodman & Renshaw Global Investment Conference Tue, 29 Aug 2017 12:50:00 +0000 JERUSALEM , August 29, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ/TASE: ORMP) ( http://www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery ...
Oramed Appoints Dr. Simon Bruce as Vice President of Medical Affairs Tue, 18 Jul 2017 12:50:00 +0000 JERUSALEM, July 18, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (ORMP) (www.oramed.com), a developer of oral drug delivery systems, announced today the appointment of Dr. Simon Bruce MD to the newly created position of Vice President of Medical Affairs. "We are very pleased to welcome Dr. Bruce on board at this pivotal time for Oramed as we prepare for the initiation of a Phase III trial for our oral insulin capsule, ORMD-0801. Dr. Bruce will be tasked with leading all of our clinical development programs, with the specific near-term focus on bringing our oral insulin (ORMD-0801) through regulatory approval and into commercialization," stated Oramed CEO, Nadav Kidron.
See what the IHS Markit Score report has to say about Blueprint Medicines Corp. Wed, 15 Nov 2017 13:07:05 +0000 Short interest is low for BPMC with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last month, ETFs holding BPMC are favorable, with net inflows of $3.03 billion.
Blueprint Medicines Corp. breached its 50 day moving average in a Bearish Manner : BPMC-US : November 15, 2017 Wed, 15 Nov 2017 12:51:12 +0000 Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Blueprint Medicines Corp.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bullish ... Read more
(Read more...)
ETFs with exposure to Blueprint Medicines Corp. : November 6, 2017 Mon, 06 Nov 2017 16:13:01 +0000 Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Blueprint Medicines Corp. Here are 5 ETFs with the largest exposure to BPMC-US. Comparing the performance and risk of Blueprint Medicines Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more
(Read more...)
Blueprint Medicines Corp. :BPMC-US: Earnings Analysis: Q3, 2017 By the Numbers : November 3, 2017 Fri, 03 Nov 2017 13:55:58 +0000 Categories: Yahoo FinanceGet free summary analysis Blueprint Medicines Corp. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Blueprint Medicines Corp. – Newlink Genetics Corporation (NLNK-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD 8.07 million, Net Earnings of USD -37.70 ... Read more
(Read more...)
Blueprint Medicines Announces Publication of BLU-285 Translational Data Wed, 01 Nov 2017 20:01:00 +0000 - Data published in Science Translational Medicine highlight the potential of BLU-285, a potent and highly selective KIT and PDGFRα inhibitor, to address unmet patient needs in GIST and SM - CAMBRIDGE, ...
Blueprint Medicines reports 3Q loss Tue, 31 Oct 2017 11:28:42 +0000 On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of 96 cents. The results did not meet Wall Street expectations. The average estimate of five analysts surveyed by Zacks ...
Blueprint Medicines Reports Third Quarter 2017 Financial Results Tue, 31 Oct 2017 11:00:00 +0000 - Presented clinical data from ongoing Phase 1 trial of BLU-554 in advanced hepatocellular carcinoma (HCC) at ESMO and ILCA 2017 Congress - - Updated BLU-285 data in advanced gastrointestinal stromal tumors ...
Markets Get Back to Business as Usual Fri, 03 Nov 2017 16:43:00 +0000 U.S. stocks move higher after early slip, as investors digest Apple's latest results.
Global Blood reports 3Q loss Thu, 02 Nov 2017 23:00:00 +0000 The South San Francisco, California-based company said it had a loss of 66 cents per share. The results fell short of Wall Street expectations. The average estimate of seven analysts surveyed by Zacks ...
DBV Shares Fall After Phase 3 Data on Peanut Allergy Treatment -- Biotech Movers Mon, 23 Oct 2017 13:15:00 +0000 The Montrouge, France-based firm on Friday unveiled top-line results from its Phase 3 study of a peanut allergy treatment. The study, dubbed Pepites, evaluated Viaskin Peanut in children four to 11 years ...
Corium Q4 Sales Top Expectations Ahead Of Slew Of Near-Term Catalysts Fri, 17 Nov 2017 14:13:30 +0000 Commercial-stage biopharma company Corium International Inc (NASDAQ: CORI ) reported Thursday 19 percent revenue growth for its fiscal year fourth quarter of 2017, while its loss per share narrowed to ...
Corium reports 4Q loss Thu, 16 Nov 2017 21:19:40 +0000 On a per-share basis, the Menlo Park, California-based company said it had a loss of 36 cents. The results beat Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...
Corium International, Inc. to Host Earnings Call Thu, 16 Nov 2017 17:10:00 +0000 NEW YORK, NY / ACCESSWIRE / November 16, 2017 / Corium International, Inc. (NASDAQ: CORI ) will be discussing their earnings results in their Q4 Earnings Call to be held on November 16, 2017 at 5:00 PM ...
Corium International, Inc. – Value Analysis (NASDAQ:CORI) : November 14, 2017 Tue, 14 Nov 2017 20:20:23 +0000 Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Corium International, Inc. a score of 13. Our analysis is based on comparing Corium International, Inc. with the following peers – Procter & Gamble Company, Merck & Co., Inc., Mylan N.V., Johnson & Johnson, Agile Therapeutics, Inc., Teva Pharmaceutical Industries Limited Sponsored ADR and Zogenix, Inc. (PG-US, ... Read more
(Read more...)
Corium International, Inc. breached its 50 day moving average in a Bullish Manner : CORI-US : November 13, 2017 Mon, 13 Nov 2017 12:22:53 +0000 Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Corium International, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish ... Read more
(Read more...)
ETFs with exposure to Corium International, Inc. : October 30, 2017 Mon, 30 Oct 2017 15:36:46 +0000 Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Corium International, Inc. Here are 5 ETFs with the largest exposure to CORI-US. Comparing the performance and risk of Corium International, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more
(Read more...)
Corium International, Inc. breached its 50 day moving average in a Bullish Manner : CORI-US : October 26, 2017 Thu, 26 Oct 2017 12:04:30 +0000 Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Corium International, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish ... Read more
(Read more...)
Why Biotech Sage Therapeutics Is Overvalued Fri, 17 Nov 2017 19:43:00 +0000 Sage's stock soared after it reported promising clinical results for its postpartum depression drug.
Sage Therapeutics Prices Public Offering of Common Stock Wed, 15 Nov 2017 02:00:00 +0000 Sage Therapeutics , a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today announced the pricing of an underwritten public offering of 3,529,411 shares of its common stock at a public offering price of $85.00 per share.
7 Life Science Stocks to Buy Today Tue, 14 Nov 2017 20:03:41 +0000 Biotech and life sciences stocks have had a great run-up so far in 2017. Through the end of October, the S&P Biotechnology Select Sector Industry Index (SPSIBI) is up 52%. That makes the life science stocks some of best performers around. And what’s not to like?
Sage Therapeutics Announces Proposed Public Offering of Common Stock Mon, 13 Nov 2017 21:01:00 +0000 Sage Therapeutics , a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today announced that it has commenced an underwritten public offering of $300.0 million of its common stock.
Sage Therapeutics takes on postpartum depression with tri... Fri, 10 Nov 2017 18:35:00 +0000 CNBC's Meg Tirrell reports on a new trial drug from Sage Therapeutics that could help fight postpartum depression. Sage CEO Dr. Jeff Jonas explains the potential of the new drug.
Enanta is a research and development-focused biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs in the infectious disease field.
Enanta Pharmaceuticals, Inc. – Value Analysis (NASDAQ:ENTA) : November 24, 2017 Fri, 24 Nov 2017 16:18:52 +0000 Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Enanta Pharmaceuticals, Inc. a score of 75. Our analysis is based on comparing Enanta Pharmaceuticals, Inc. with the following peers – Achillion Pharmaceuticals, Inc., Enzon Pharmaceuticals, Inc., Vertex Pharmaceuticals Incorporated, Johnson & Johnson, AbbVie, Inc., Novartis AG Sponsored ADR, Merck & Co., Inc. and Bristol-Myers Squibb Company ... Read more
(Read more...)
Enanta Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ENTA-US : November 22, 2017 Wed, 22 Nov 2017 12:53:39 +0000 Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Enanta Pharmaceuticals, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bullish ... Read more
(Read more...)
ETFs with exposure to Enanta Pharmaceuticals, Inc. : November 21, 2017 Tue, 21 Nov 2017 16:41:11 +0000 Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Enanta Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to ENTA-US. Comparing the performance and risk of Enanta Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more
(Read more...)
Enanta Pharmaceuticals posts 4Q profit Mon, 20 Nov 2017 21:25:55 +0000 The Watertown, Massachusetts-based company said it had profit of $1.86 per share. The biotechnology company posted revenue of $75.9 million in the period. For the year, the company reported profit of $17.7 ...
Enanta Pharmaceuticals, Inc. to Host Earnings Call Mon, 20 Nov 2017 17:00:00 +0000 NEW YORK, NY / ACCESSWIRE / November 20, 2017 / Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA ) will be discussing their earnings results in their Q4 Earnings Call to be held on November 20, 2017 at 4:30 ...
Enanta Pharmaceuticals Ranked as One of North America’s Fastest Growing Companies on Deloitte’s 2017 Technology Fast 500™ Fri, 10 Nov 2017 12:30:00 +0000 Enanta Pharmaceuticals, Inc. , a chemistry-driven biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced its inclusion on Deloitte’s Technology Fast 500™, a ranking of the 500 fastest growing technology, media, telecommunications, life sciences and energy tech companies in North America.
Corporate News Blog - Cerecor Acquired TRx Pharmaceuticals Tue, 21 Nov 2017 12:40:00 +0000 Research Desk Line-up: AscendisPharmaPostEarnings Coverage LONDON, UK / ACCESSWIRE / November 21, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Cerecor ...
Ascendis Pharma A/S Reports Third Quarter 2017 Financial Results Thu, 16 Nov 2017 21:01:00 +0000 -Phase 3 Program for TransCon Growth Hormone Advances and TransCon PTH Enters the Clinic-. -Conference Call Today at 4:30 p.m. Eastern Time-. COPENHAGEN, Denmark, Nov. 16, 2017-- Ascendis Pharma A/S, a ...
Ascendis Pharma A/S Sponsored ADR to Host Earnings Call Thu, 16 Nov 2017 17:00:00 +0000 NEW YORK, NY / ACCESSWIRE / November 16, 2017 / Ascendis Pharma A/S Sponsored ADR (NASDAQ: ASND ) will be discussing their earnings results in their Q3 Earnings Call to be held on November 16, 2017 at ...
Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs Wed, 27 Sep 2017 04:16:41 +0000 COPENHAGEN, Denmark, Sept. 27, 2017-- Ascendis Pharma A/S, a clinical stage biopharmaceutical company, today announced the pricing of its underwritten public offering of 3,800,000 American Depositary Shares, ...
Ascendis Pharma A/S Announces Dosing of Subjects in Phase 1 Trial of TransCon PTH Tue, 26 Sep 2017 12:00:00 +0000 COPENHAGEN, Denmark, Sept. 26, 2017-- Ascendis Pharma A/S, a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet medical needs in rare diseases, announced ...
Novocure Shares Jump on Phase 3 Data Analysis -- Biotech Movers Fri, 17 Nov 2017 14:26:00 +0000 Oncology firm released results that show increased compliance with Optune predicted increased survival in patients with glioblastoma, a form of brain cancer.
ETFs with exposure to Revance Therapeutics, Inc. : November 13, 2017 Mon, 13 Nov 2017 18:08:46 +0000 Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Revance Therapeutics, Inc. Here are 5 ETFs with the largest exposure to RVNC-US. Comparing the performance and risk of Revance Therapeutics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more
(Read more...)
Revance Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : RVNC-US : November 10, 2017 Fri, 10 Nov 2017 12:57:37 +0000 Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Revance Therapeutics, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bullish ... Read more
(Read more...)
Revance Therapeutics, Inc. :RVNC-US: Earnings Analysis: Q3, 2017 By the Numbers : November 7, 2017 Tue, 07 Nov 2017 13:02:20 +0000 Categories: Yahoo FinanceGet free summary analysis Revance Therapeutics, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Revance Therapeutics, Inc. – Johnson & Johnson and Biogen Inc. (JNJ-US and BIIB-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD 0.08 million, ... Read more
(Read more...)
Revance reports 3Q loss Thu, 02 Nov 2017 22:50:15 +0000 The Newark, California-based company said it had a loss of $1.01 per share. The results did not meet Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...
Revance Therapeutics, Inc. – Value Analysis (NASDAQ:RVNC) : October 31, 2017 Tue, 31 Oct 2017 16:19:41 +0000 Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Revance Therapeutics, Inc. a score of 17. Our analysis is based on comparing Revance Therapeutics, Inc. with the following peers – Valeant Pharmaceuticals International Inc, MediciNova, Inc., Johnson & Johnson, Biogen Inc., Ionis Pharmaceuticals, Inc. and Tenax Therapeutics, Inc. (VRX-US, MNOV-US, JNJ-US, BIIB-US, IONS-US and TENX-US). Investment ... Read more
(Read more...)
ETFs with exposure to Revance Therapeutics, Inc. : October 31, 2017 Tue, 31 Oct 2017 15:49:55 +0000 Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Revance Therapeutics, Inc. Here are 5 ETFs with the largest exposure to RVNC-US. Comparing the performance and risk of Revance Therapeutics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more
(Read more...)
Revance Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : RVNC-US : October 30, 2017 Mon, 30 Oct 2017 12:11:07 +0000 Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Revance Therapeutics, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish ... Read more
(Read more...)
Esperion to Participate in Fireside Chat at the Stifel 2017 Healthcare Conference Thu, 09 Nov 2017 21:30:00 +0000 Fireside Chat Webcast on Tuesday, November 14, 2017 at 8:45 a.m. Eastern Time. ANN ARBOR, Mich., Nov. 09, 2017-- Esperion Therapeutics, Inc., the Lipid Management Company focused on developing and commercializing ...
Esperion to Host Analyst and Investor Day Event on October 17 Tue, 10 Oct 2017 12:30:00 +0000 ANN ARBOR, Mich., Oct. 10, 2017-- Esperion Therapeutics, Inc., the Lipid Management Company focused on developing and commercializing convenient, complementary, cost-effective, once-daily, oral therapies ...
*Winners defined as our Top Picks that increased 20% or more within a 6-month period.
Red Letters imply that that particular criteria did not meet minimum requirements, e.g., a low GSA Rank would show it in red.
___ Red Line On Graph Shows a Trailing Stop Loss Based on Support and Resistance Levels. See how it works.
___ Blue Line On Graph Shows the 10-Week Moving Average.
___ Magenta Line On Graph Shows the 40-Week Moving Average.
Disclaimer The stock selections in our stock investing and stock trading database are not stock recommendations, but simply represent applications of a stock investing process. All materials, including our Top Stock Picks, are provided for information purposes only and should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security. Growth Stock Analytics, LLC is not responsible for gains/losses that may result in investing or trading in these securities. All information is believed to be obtained from reliable sources, but there is no guarantee that the information supplied is accurate, complete or timely. There is no guarantee or warranty with regard to the results obtained from its use. There is no guarantee of suitability or potential value of any particular investment or information source. You acknowledge that your requests for this information are unsolicited and shall neither constitute nor be considered investment advice. Past investing performance is not an indication of future performance results. Investing and trading in stocks is risky. Investors are encouraged to consult a registered stock broker or investment adviser before making any investing decisions. The interpretations and opinions expressed herein are solely those of Growth Stock Analytics, LLC, and not of any other individual or organization.
Accum/Dist: 1.79 (median winner: 1.53)
Instit. Ownership: 84% (median winner: 63%)
Disclaimer The stock selections in our stock investing and stock trading database are not stock recommendations, but simply represent applications of a stock investing process. All materials, including our Top Stock Picks, are provided for information purposes only and should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security. Growth Stock Analytics, LLC is not responsible for gains/losses that may result in investing or trading in these securities. All information is believed to be obtained from reliable sources, but there is no guarantee that the information supplied is accurate, complete or timely. There is no guarantee or warranty with regard to the results obtained from its use. There is no guarantee of suitability or potential value of any particular investment or information source. You acknowledge that your requests for this information are unsolicited and shall neither constitute nor be considered investment advice. Past investing performance is not an indication of future performance results. Investing and trading in stocks is risky. Investors are encouraged to consult a registered stock broker or investment adviser before making any investing decisions. The interpretations and opinions expressed herein are solely those of Growth Stock Analytics, LLC, and not of any other individual or organization.